PE20070325A1 - Formas de dosificacion oral que comprenden compuestos derivados de carbamato - Google Patents
Formas de dosificacion oral que comprenden compuestos derivados de carbamatoInfo
- Publication number
- PE20070325A1 PE20070325A1 PE2006000742A PE2006000742A PE20070325A1 PE 20070325 A1 PE20070325 A1 PE 20070325A1 PE 2006000742 A PE2006000742 A PE 2006000742A PE 2006000742 A PE2006000742 A PE 2006000742A PE 20070325 A1 PE20070325 A1 PE 20070325A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- oral dosage
- compounds
- compound
- dosage forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE UN COMPUESTO DE FORMULA (I) O UN COMPUESTO DE FORMULA (II), DONDE X ES UN HALOGENO; R1, R2, R3, R4, R5 Y R6 SON H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON FENILO QUE ESTA OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), NH, NITRO O CN; DICHOS COMPUESTOS COMPRENDEN ENANTIOMEROS DE FORMULA (Ia), (IIa), ENTRE OTROS, O MEZCLAS RACEMICAS DE LOS MISMOS, EN DONDE PREDOMINA UN ENANTIOMERO EN UNA CANTIDAD DE 90%. SE REFIERE TAMBIEN A UNA ESTRUCTURA DE DOSIFICACION ORAL DE LIBERACION SOSTENIDA QUE LIBERA DE MODO SOSTENIDO EL COMPUESTO DE FORMULA (I) O (II) A VELOCIDADES QUE PROVEEN UNA CONCENTRACION PLASMATICA MAXIMA PROMEDIO DE DOSIS UNICA Cmax DEL COMPUESTO DE FORMULA (I) O (II), QUE SATISFACEN LA RELACION 5ng/ml/mg £ Cmax £ 16ng/ml/mg; Y DISPOSITIVOS QUE PERMITAN UNA DOSIFICACION DE DICHOS COMPUESTOS DE MODO QUE REDUZCA SUS EFECTOS SECUNDARIOS. LA CANTIDAD LIBERADA DE LOS COMPUESTOS DE LA FORMA DE DOSIFICACION ORAL A LAS 2 HORAS ES DE 10% EN PESO DE LA DOSIS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CONVULSIONES, EPILEPSIA, ATAQUE APOPLEJICO, ESPASMO MUSCULAR
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69571505P | 2005-06-29 | 2005-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070325A1 true PE20070325A1 (es) | 2007-05-12 |
Family
ID=37310173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000742A PE20070325A1 (es) | 2005-06-29 | 2006-06-27 | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070004797A1 (es) |
EP (1) | EP1898885A1 (es) |
AR (1) | AR054524A1 (es) |
CA (1) | CA2613933A1 (es) |
PE (1) | PE20070325A1 (es) |
TW (1) | TW200740429A (es) |
WO (1) | WO2007002906A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
CN101188999B (zh) * | 2005-06-03 | 2012-07-18 | 尹格莱特股份有限公司 | 用于递送分散在分散介质中的活性物质的药物传递系统 |
US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
EP2104493A2 (en) * | 2007-01-16 | 2009-09-30 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
US20080292692A1 (en) * | 2007-05-21 | 2008-11-27 | Shira Pilch | Impermeable Capsules |
EP2155167A2 (en) * | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
BRPI0815387B8 (pt) | 2007-08-13 | 2021-05-25 | Abuse Deterrent Pharmaceutical Llc | composição farmacêutica, método para fazer uma composição farmacêutica e uso da composição farmacêutica |
NZ594071A (en) * | 2009-01-26 | 2013-01-25 | Egalet Ltd | Controlled release formulations comprising morphine sulphate for continuous treatment of pain |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
DK2393487T3 (en) | 2009-02-06 | 2017-01-23 | Egalet Ltd | Pharmaceutical compositions resistant to abuse |
WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
EP2720686A4 (en) * | 2011-06-15 | 2014-12-17 | Orient Pharma Co Ltd | MULTILAYER CAPSULE AND MANUFACTURING METHOD THEREFOR |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
WO2002067926A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating movement disorders |
AU2005287174B2 (en) * | 2004-09-16 | 2012-01-12 | Janssen Pharmaceutica, N.V. | Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy |
-
2006
- 2006-06-27 PE PE2006000742A patent/PE20070325A1/es not_active Application Discontinuation
- 2006-06-28 TW TW095123239A patent/TW200740429A/zh unknown
- 2006-06-28 AR ARP060102781A patent/AR054524A1/es not_active Application Discontinuation
- 2006-06-29 CA CA002613933A patent/CA2613933A1/en not_active Abandoned
- 2006-06-29 EP EP06786031A patent/EP1898885A1/en not_active Withdrawn
- 2006-06-29 US US11/478,241 patent/US20070004797A1/en not_active Abandoned
- 2006-06-29 WO PCT/US2006/025692 patent/WO2007002906A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2613933A1 (en) | 2007-01-04 |
TW200740429A (en) | 2007-11-01 |
EP1898885A1 (en) | 2008-03-19 |
US20070004797A1 (en) | 2007-01-04 |
WO2007002906A1 (en) | 2007-01-04 |
AR054524A1 (es) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070325A1 (es) | Formas de dosificacion oral que comprenden compuestos derivados de carbamato | |
PE20060285A1 (es) | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) | |
AR052156A1 (es) | Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos | |
PE20040832A1 (es) | Derivados de indolil pirazinona | |
PE20110215A1 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
AR061737A1 (es) | Compuestos derivados de pirimidina, un peoceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20040512A1 (es) | Compuesto de pirazol-pirimidina anilina | |
TW200508180A (en) | Therapeutic agents | |
UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
BRPI0515374A (pt) | métodos de tratamento de epileptogenêse e epilepsia | |
PE20100737A1 (es) | Nuevos compuestos | |
PE20050484A1 (es) | Composicion farmaceutica de liberacion sostenida | |
AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
PE20080929A1 (es) | Metodos para el tratamiento de la depresion | |
PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
YU68003A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja | |
GT200300183A (es) | Nuevos agonistas ppar-alfa y ppar-gamma | |
AR033427A1 (es) | Uso de compuestos carbamatos en el tratamiento del dolor | |
MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
ECSP088602A (es) | Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides | |
AR032876A1 (es) | Compuestos de carbamato para utilizar en la prevencion o tratamiento de los trastornos psicoticos | |
PE20061113A1 (es) | Compuestos heterociclos como agonistas de ligandos selectivos de erb | |
PE20040943A1 (es) | 2-AMINOIMIDAZOLES SUSTITUIDOS COMO INHIBIDORES DEL INTERCAMBIADOR Na/H SUBTIPO 3 (NHE 3) | |
UY27560A1 (es) | Compuestos hexaciclicos- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |